Corneal ulcers are an ocular emergency and a leading cause of blindness globally. The treatment regimen usually requires hourly (or in some cases, even more frequent) round-the-clock administration of topical antibiotics, which is inconvenient and leads to compliance challenges, increasing the burden of care. Researchers evaluated the capability of a crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) topical gel, Ocular Bandage Gel (OBG), as a viable sustained-release delivery system for small molecule antibiotic drugs in comparison to standard vehicle formulations. Results showed that the OBG had significantly slowed down the release of two frequently used fluoroquinolone antibiotics, moxifloxacin and besifloxacin, and exhibited longer retention time on the surface of the eye. This may allow for less frequent dosing, demonstrating the OBG’s overall viability as a delivery system.
EyeGate Pharmaceuticals’ most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S). Their proprietary Ocular Bandage Gel has the ability to adhere longer to the ocular surface, resist degradation, and protect the ocular surface making it well-suited for treating various ocular surface injuries.
The poster can be viewed by clicking here.